Additionally, a cost-utility analysis of a simulated cohort of 100,000 participants in the United Kingdom found that GAAD was cost-effective, compared with ultrasound alone and ultrasound combined with AFP measurements, in participants with compensated liver cirrhosis (CLC)44. The gene discussed is AFP; the disease is cirrhosis of liver.